• 1
    Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277:12931298.
  • 2
    Kannel WB. Hypertension as a risk factor for cardiac events – epidemiologic results of long-term studies. J Cardiovasc Pharmacol. 1993;21(suppl 2):S27S37.
  • 3
    Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. [see comments]. JAMA. 1991;265:32553264.
  • 4
    Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000;356:19551964.
  • 5
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:20432050.
  • 6
    DiMatteo MR, Giordani PJ, Lepper HS, et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794811.
  • 7
    Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manage Care Pharm. 2006;12:239245.
  • 8
    Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722732.
  • 9
    Ogedegbe G, Harrison M, Robbins L, et al. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study. Ethn Dis. 2004;14:312.
  • 10
    Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19:357362.
  • 11
    Cummings KM, Kirscht JP, Binder LR, et al. Determinants of drug treatment maintenance among hypertensive persons in inner city Detroit. Public Health Rep. 1982;97:99106.
  • 12
    DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45:521528.
  • 13
    Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:6774.
  • 14
    Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15:9096.
  • 15
    Tilburt JC, Dy SM, Weeks K, et al. Associations between home remedy use and a validated self-reported adherence measure in an urban African-American population with poorly controlled hypertension. J Natl Med Assoc. 2008;100:9197.
  • 16
    Ware JE, Snow KK, Kosisnki M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: The Health Institute; 1993.
  • 17
    Ware JE, Kosisnki M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User’s Manual. Boston, MA: The Health Institute; 1994.
  • 18
    Wang PS, Bohn RL, Knight E, et al. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med. 2002;17:504511.
  • 19
    Siegel D, Lopez J, Meier J. Antihypertensive medication adherence in the Department of Veterans Affairs. Am J Med. 2007;120:2632.
  • 20
    Morris AB, Li J, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26:483492.
  • 21
    Lukoschek P. African Americans’ beliefs and attitudes regarding hypertension and its treatment: a qualitative study. J Health Care Poor Underserved. 2003;14:566587.
  • 22
    Rose LE, Kim MT, Dennison CR, et al. The contexts of adherence for African Americans with high blood pressure. J Adv Nurs. 2000;32:587594.
  • 23
    Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med. 1992;34:507513.
  • 24
    Enlund H, Jokisalo E, Wallenius S, et al. Patient-perceived problems, compliance, and the outcome of hypertension treatment. Pharm World Sci. 2001;23:6064.
  • 25
    Hyre AD, Krousel-Wood MA, Muntner P, et al. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich). 2007;9:179186.
  • 26
    Cook CA. Antihypertensive drug compliance in black males. J Natl Med Assoc. 1984;76(suppl):4046.
  • 27
    Fongwa MN, Evangelista LS, Doering LV. Adherence to treatment factors in hypertensive African American women. J Cardiovasc Nurs. 2006;21:201207.
  • 28
    Shea S, Misra D, Ehrlich MH, et al. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health. 1992;82:16071612.
  • 29
    Shakoor-Abdullah B, Kotchen JM, Walker WE, et al. Incorporating socio-economic and risk factor diversity into the development of an African-American community blood pressure control program. Ethn Dis. 1997;7:175183.
  • 30
    Kim MT, Han HR, Hill MN, et al. Depression, substance use, adherence behaviors, and blood pressure in urban hypertensive black men. Ann Behav Med. 2003;26:2431.